For research use only. Not for therapeutic Use.
TPPB is a cell-permeable benzolactam-derived protein kinase C (PKC) activator with a Ki of 11.9 nM.
By use of a cell line derived from an Alzheimer’s disease patient, significant enhancement of sAPPα secretion is achieved at 1 μM concentration for TPPB (Compound 5e)[1]. TPPB has a role against Aβ25-35-induced neurotoxicity in PC12 cells. TPPB at concentration of 1 μM could antagonize Aβ25-35 induced cell damage. TPPB could increase the phosphorylation of Akt, PKC, MARCKS and MAPK, which are inhibited by Aβ25-35 treatment. TPPB inhibits the activation of caspase-3 induced by Aβ25-35[2].
TPPB is evaluated for induction of hyperplasia after topical application to the shaved backs of outbred Sencar mice and shows a modest response at 300 μg[1].
| Catalog Number | I011172 |
| CAS Number | 497259-23-1 |
| Synonyms | (2E,4E)-N-[(2S,5S)-5-(hydroxymethyl)-1-methyl-3-oxo-2-propan-2-yl-2,4,5,6-tetrahydro-1,4-benzodiazocin-8-yl]-5-[4-(trifluoromethyl)phenyl]penta-2,4-dienamide |
| Molecular Formula | C27H30F3N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C27H30F3N3O3/c1-17(2)25-26(36)32-22(16-34)15-19-14-21(12-13-23(19)33(25)3)31-24(35)7-5-4-6-18-8-10-20(11-9-18)27(28,29)30/h4-14,17,22,25,34H,15-16H2,1-3H3,(H,31,35)(H,32,36)/b6-4+,7-5+/t22-,25-/m0/s1 |
| InChIKey | WOLVEMPZUIFSII-IHHOKICGSA-N |
| SMILES | CC(C)C1C(=O)NC(CC2=C(N1C)C=CC(=C2)NC(=O)C=CC=CC3=CC=C(C=C3)C(F)(F)F)CO |
| Reference | [1]. Kozikowski AP, et al. New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPPalpha. J Med Chem. 2003 Jan 30;46(3):364-73. [2]. Yang HQ, et al. Neuroprotective effects of new protein kinase C activator TPPB against Aβ25-35 induced neurotoxicity in PC12 cells. Neurochem Res. 2012 Oct;37(10):2213-21. |
